Catheter Precision (VTAK) CEO awarded 40,000 options at $1.15 exercise price

Rhea-AI Filing Summary

Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share, expire on March 26, 2036, and vest 100% 180 days after the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider JENKINS DAVID A

Role Chairman of the Board and CEO

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Options (Right to Buy) — 40,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 40,000 options Exercise price: $1.15 per share Underlying shares: 40,000 shares +2 more

5 metrics

Options granted 40,000 options Grant of options to CEO on March 26, 2026

Exercise price $1.15 per share Exercise price for newly granted options

Underlying shares 40,000 shares Common stock underlying the option grant

Expiration date March 26, 2036 Option term end date

Post-transaction derivatives 40,000 options Derivative holdings following this grant

Key Terms

Options (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Options (Right to Buy) financial

"security_title: "Options (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-03-26T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

vest 100% on 180 day anniversary financial

"Options vest 100% on 180 day anniversary of grant date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JENKINS DAVID A

(Last) (First) (Middle)

1670 HIGHWAY 160 WEST

SUITE 205

(Street)

FORT MILL SOUTH CAROLINA 29708

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman of the Board and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.15	03/26/2026		A		40,000		(1)	03/26/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. Options vest 100% on 180 day anniversary of grant date.

	/s/ David A. Jenkins	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Catheter Precision (VTAK) report for David A. Jenkins?

Catheter Precision reported that Chairman and CEO David A. Jenkins received a grant of options for 40,000 shares of common stock. These options are a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of the new options granted to the VTAK CEO?

The options granted to the CEO have an exercise price of $1.15 per share. This means Jenkins can buy Catheter Precision common stock at $1.15 once the options vest and are exercised, regardless of the future market price.

When do the Catheter Precision (VTAK) CEO’s options vest and become exercisable?

The options granted to the CEO vest 100% on the 180-day anniversary of the March 26, 2026 grant date. After vesting, he can choose to exercise them any time before the expiration date, subject to applicable plan and company rules.

How many Catheter Precision (VTAK) shares underlie the CEO’s new option grant?

The option grant covers 40,000 underlying shares of Catheter Precision common stock. Each option represents the right to purchase one share at the fixed exercise price once the award vests and is exercised.

When do the newly granted VTAK CEO options expire?

The options granted to the CEO expire on March 26, 2036. If they are not exercised by that expiration date, the right to buy Catheter Precision common stock under this grant will lapse and become worthless.